BioCentury
ARTICLE | Clinical News

NSL-101: Phase II started

December 3, 2007 8:00 AM UTC

NDL began a double-blind, Peruvian Phase II trial in 50 patients to compare NSL-101 to placebo after 24 weeks. The company has a worldwide license to NSL-101 from Ampika Ltd. ...